6-thioguanine selectively kills BRCA2 defective tumours and overcomes PARP inhibitor resistance

Familial breast and ovarian cancers are often defective in homologous recombination (HR) due to mutations in the BRCA1 or BRCA2 genes. Cisplatin chemotherapy or poly(ADP-ribose) polymerase (PARP) inhibitors are tested for these tumours in clinical trials. In a screen for novel drugs that selectively...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Issaeva, Natalia, Thomas, Huw D., Djurenovic, Tatjana, Jaspers, Janneke E., Stoimenov, Ivaylo, Kyle, Suzanne, Pedley, Nicholas, Gottipati, Ponnari, Zur, Rafal, Sleeth, Kate, Chatzakos, Vicky, Mulligan, Evan, Lundin, Cecilia, Gubanova, Evgenia, Kersbergen, Ariena, Harris, Adrian L, Sharma, Ricky A, Rottenberg, Sven, Curtin, Nicola J., Helleday, Thomas
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2913123/
https://ncbi.nlm.nih.gov/pubmed/20631063
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-09-3416
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados